Molecular Screening Services

Tender description

This Contract notice is a call for competition and is separate to any tender opportunity. Its purpose is to inform the market of a tender opportunity. NHS Blood and Transplant are looking for a Managed Service provider to provide a fully integrated high throughput testing solution for an automated Nucleic Acid Amplification Testing (NAT) system which can detect HBV DNA, HIV-1 RNA, HIV-2 RNA, HCV RNA, HEV RNA in EDTA plasma from blood and non-blood (e.g. stem cell, tissue) donors including from deceased (non-heart beating) donors. The solution must have the relevant CE/UKCA marking to support this ability.<br/>Participation is subject to the Supplier currently participating in the NHSBT KEG process, or confirmation that their testing solution has previously been KEG approved to deliver Molecular Screening in partnership with NHSBT. All correspondence to: tennille.madigan@nhsbt.nhs.uk Lot 1: This is separate to any tender opportunity. Its purpose is to inform the market of the Molecular Screening tender opportunity. NHSBT are looking for a fully integrated high throughput testing solution for an automated Nucleic Acid Amplification Testing (NAT) system which can detect HBV DNA, HIV-1 RNA, HIV-2 RNA, HCV RNA, HEV RNA in EDTA plasma from blood and non-blood (e.g. stem cell, tissue) donors including from deceased (non-heart beating) donors. The solution must have the relevant CE/UKCA marking to support this ability and be currently taking part in KEG to gain approval or already have approval from KEG to undertake this service.